APVO
Aptevo Therapeutics Inc.·Healthcare
4.44
1.602%(+0.07)
Market ClosedLast Updated: — ET
52W L: $3.8052W H: $486.00
APVO NEWS
zacks.com
1d ago
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
accessnewswire.com
Mar 26
Aptevo Provides State of the Business Report and 2025 Financial Results
Latest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 frontline AML patients, supporting its potential to enhance standard-of-care combination therapy Company expands CD3 pipeline and introduces first trispecific drug candidates SEATTLE, WA / ACCESS Newswire / March 26, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR TM and ADAPTIR-FLEX TM platform technologies, today reported financial results for the year ended December 31, 2025 and provided a business update highlighting recent clinical progress, pipeline expansion and capital strategy. "2025 was a year of meaningful progress across our clinical programs, pipeline strategy and capital position," said Marvin White, President and Chief Executive Officer of Aptevo Therapeutics.
accessnewswire.com
Mar 19
Aptevo to Participate in March 2026 Conferences
SEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced its participation in the following March conferences: The 38th Annual Roth Conference March 22-24, 2026, in Dana Point, CA. Aptevo incoming President and Chief Executive Officer Jeff Lamothe will participate in a Company-focused fireside chat with analyst Jonathan Aschoff.
defenseworld.net
Mar 18
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Decline in Short Interest
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 116,763 shares, a decline of 12.6% from the February 12th total of 133,525 shares. Based on an average trading volume of 20,886 shares,
accessnewswire.com
Mar 10
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients who are either elderly or unfit for intensive chemotherapy. In data from two trials, the combination has demonstrated robust clinical activity, delivering an 86% clinical benefit rate (CR/CRi/PR*)with zero patients experiencing the common symptom of cytokine release syndrome (CRS).
defenseworld.net
Feb 16
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Drop in Short Interest
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 152,186 shares, a decrease of 30.8% from the January 15th total of 219,920 shares. Based on an average daily volume of 72,754 shares,
